May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Factors determining the degree of response to latanoprost in patients with glaucoma or ocular hypertension in usual care practice
Author Affiliations & Notes
  • P. Fernandez–Vila
    Ophthalmology, HOSP. PROVINCIAL PONTEVEDRA, Pontevedra, Spain
  • Xalatan Response Study Group
    Ophthalmology, HOSP. PROVINCIAL PONTEVEDRA, Pontevedra, Spain
  • Footnotes
    Commercial Relationships  P. Fernandez–Vila, None.
  • Footnotes
    Support  Pfizer Spain Grant
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5549. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Fernandez–Vila, Xalatan Response Study Group; Factors determining the degree of response to latanoprost in patients with glaucoma or ocular hypertension in usual care practice . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5549.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To identify demographic and clinical factors linked to hyperresponse or hyporesponse to latanoprost therapy in everyday practice. Methods: This open–label, observational, multicentre (124 Spanish centres) study included patients with primary open–angle glaucoma or high intraocular pressure (IOP) levels who received latanoprost monotherapy for 1–3 months as first–line therapy or following washout of previous therapy; 375 consecutive eligible patients were assigned to one of the two preestablished groups (hyperresponders=IOP reduction >30%, n=284 [76%]; hyporesponders=IOP reduction <15%, n=91 [24%]). Data for each patient were collected in a single visit and included IOP, and epidemiological and clinical variables. Descriptive analyses, t tests, and chi–square tests were performed. Results: Hyporesponders were more likely than hyperresponders to have received ocular hypotensive therapy before latanoprost (37% vs 21%, P=.002), have undergone ocular surgery (13% vs 4%, P=.002), and have had a longer delay between initial glaucoma diagnosis and latanoprost administration (16.7+29.7 vs 9.7+24.3 months, P=.055). Hyperresponders had a higher IOP at diagnosis (27.5+4.3 mmHg vs 25.4+3.6 mmHg, P=.055) and immediately prior to initiating latanoprost therapy (IOP >28 mmHg: 34% vs 11%, P<.0001) No association between responsiveness to latanoprost and clinical features of glaucoma, cup–disk ratio, gonioscopy, eye colour, age, gender, race, previous uveitis, or refractive status was shown. Conclusions: Latanoprost response of <15% occurred in fewer than one quarter of patients and was associated primarily with disease progression and time of latanoprost initiation rather than to patient–related ocular factors.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • intraocular pressure 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.